- Home
- CSBR vs GNTA Comparison
CSBR vs GNTA Comparison
Compare CSBR & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- GNTA
- Stock Information
- Founded
- CSBR 1985
- GNTA 2014
- Country
- CSBR United States
- GNTA Italy
- Employees
- CSBR N/A
- GNTA N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSBR Health Care
- GNTA Health Care
- Exchange
- CSBR Nasdaq
- GNTA Nasdaq
- Market Cap
- CSBR 98.1M
- GNTA 96.0M
- IPO Year
- CSBR 1986
- GNTA 2021
- Fundamental
- Price
- CSBR $10.69
- GNTA $3.98
- Analyst Decision
- CSBR Strong Buy
- GNTA Strong Buy
- Analyst Count
- CSBR 1
- GNTA 1
- Target Price
- CSBR $8.00
- GNTA $25.00
- AVG Volume (30 Days)
- CSBR 73.5K
- GNTA 21.3K
- Earning Date
- CSBR 03-11-2025
- GNTA 01-01-0001
- Dividend Yield
- CSBR N/A
- GNTA N/A
- EPS Growth
- CSBR N/A
- GNTA N/A
- EPS
- CSBR N/A
- GNTA N/A
- Revenue
- CSBR $53,571,000.00
- GNTA N/A
- Revenue This Year
- CSBR $14.19
- GNTA N/A
- Revenue Next Year
- CSBR $10.11
- GNTA N/A
- P/E Ratio
- CSBR N/A
- GNTA N/A
- Revenue Growth
- CSBR 7.19
- GNTA N/A
- 52 Week Low
- CSBR $3.60
- GNTA $2.20
- 52 Week High
- CSBR $10.90
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- CSBR 69.42
- GNTA 34.55
- Support Level
- CSBR $9.00
- GNTA $3.51
- Resistance Level
- CSBR $10.90
- GNTA $5.45
- Average True Range (ATR)
- CSBR 0.80
- GNTA 0.55
- MACD
- CSBR -0.00
- GNTA -0.10
- Stochastic Oscillator
- CSBR 93.04
- GNTA 13.90
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.